NRIX Stock News & Analysis | Latest Updates

Nurix Therapeutics to Participate in Upcoming Investor Conferences

(NASDAQ:NRIX) SAN FRANCISCO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer, Hans van Houte, chief financial officer, John Northcott, chief commercial officer, and Jason Kantor, Ph.D., chief business officer, will participate in several investor conferences in September.

August 28, 2025Investor

NRIX News

Nurix Therapeutics to Participate in Upcoming Investor Conferences

Nurix Reports 81% Response Rate in CLL Drug Trial, With Complete Remission in Long-Term Patient

Sanofi Has Exercised Its Option To Exclusively License Nurix Therapeutics' STAT6 Program, Including The Drug Development Candidate NX-3911, Nurix To Receive A $15M License Extension Fee From Sanofi Under Its 2019 Collaboration Agreement

Nurix Therapeutics Prersents Data From Ongoing Phase 1a/b Clinical Trial Of Bexobrutideg In Patients With r/r CLL And Waldenström Macroglobulinemia At EHA Congress 2025 And 18-ICML

Breaking Down Nurix Therapeutics: 7 Analysts Share Their Views

Needham Reiterates Buy on Nurix Therapeutics, Maintains $27 Price Target

Nurix Therapeutics Presents Data at AACR 2025 Highlighting Transformative Potential of Proprietary DEL-AI Platform Leveraging Machine Learning To Speed Discovery Of Novel Drugs

Nurix Therapeutics Says FDA Clears IND for IRAK4 Degrader GS-6791/NX-0479, Enabling Initiation Of Phase 1 trial, Which Is Expected To Begin in Q2 2025

Wells Fargo Maintains Overweight on Nurix Therapeutics, Lowers Price Target to $25

Stifel Maintains Buy on Nurix Therapeutics, Lowers Price Target to $35

Needham Maintains Buy on Nurix Therapeutics, Lowers Price Target to $27

Nurix Therapeutics Q1 EPS $(0.67) Beats $(0.78) Estimate, Sales $18.45M Beat $12.71M Estimate

Expert Outlook: Nurix Therapeutics Through The Eyes Of 9 Analysts

HC Wainwright & Co. Reiterates Buy on Nurix Therapeutics, Maintains $36 Price Target

Nurix Licenses Drug Discovery Program To Sanofi Targeting Novel Transcription Factor For Autoimmune Diseases; Is Eligible For Additional $465M In Milestones Plus Royalties

Nurix Therapeutics To Present Preclinical Data From Proprietary DEL-AI Platform At The American Association For Cancer Research Annual Meeting, From April 25-30, 2025

Beyond The Numbers: 8 Analysts Discuss Nurix Therapeutics Stock

Leerink Partners Initiates Coverage On Nurix Therapeutics with Market Perform Rating, Announces Price Target of $16

The FDA Has Granted Orphan Drug Designation To Nurix Therapeutics' Bexobrutideg (NX-5948) For The Treatment Of Waldenström Macroglobulinemia

Nurix Therapeutics Outlined Key Objectives And Anticipated Milestones For 2025, Which Will Be The Subject Of Nurix's Corporate Update At The Annual J.P. Morgan Healthcare Conference

Nurix Says FDA Granted Fast Track Designation For NX-5948 For Treatment Of Adult Patients With Relapsed Or Refractory Waldenstrom's Macroglobulinemia After At Least Two Lines Of Therapy

Nurix Therapeutics Receives PRIME Designation From European Medicines Agency For NX-5948 For Relapsed Or Refractory Chronic Lymphocytic Leukemia

Reported Sunday, Nurix Therapeutics Showcased Preclinical Data On NX-5948 And GS-6791 From Autoimmune And Inflammatory Disease Programs At ACR Convergence 2024

The Analyst Verdict: Nurix Therapeutics In The Eyes Of 10 Experts

Needham Reiterates Buy on Nurix Therapeutics, Maintains $29 Price Target

Nurix Therapeutics To Present Data At 66th ASH Annual Meeting

Nurix Therapeutics Says David Lacey Steps Down From Chair Role And Will Remain Board Member And Retain Committee Leadership Roles; Current Board Member Julia Gregory Elected New Board Chair